Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 17975552 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Dey A, et al. (2008) R-Roscovitine simultaneously targets both the p53 and NF-kappaB pathways and causes potentiation of apoptosis: implications in cancer therapy. Cell Death Differ 15, 263-73 17975552
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S32-p - IkB-alpha (human)
Orthologous residues
IkB‑alpha (human): S32‑p, IkB‑alpha (mouse): S32‑p, IkB‑alpha (rat): S32‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  A549 (pulmonary), NCI-H1299 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TNF increase
roscovitine TNF inhibit treatment-induced increase

S36-p - IkB-alpha (human)
Orthologous residues
IkB‑alpha (human): S36‑p, IkB‑alpha (mouse): S36‑p, IkB‑alpha (rat): S36‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  A549 (pulmonary), NCI-H1299 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TNF increase
roscovitine TNF inhibit treatment-induced increase

S176-p - IKKA (human)
Orthologous residues
IKKA (human): S176‑p, IKKA (mouse): S176‑p, IKKA (rat): S176‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  A549 (pulmonary), NCI-H1299 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TNF increase
roscovitine increase
roscovitine TNF no effect upon treatment-induced increase

S180-p - IKKA (human)
Orthologous residues
IKKA (human): S180‑p, IKKA (mouse): S180‑p, IKKA (rat): S180‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  A549 (pulmonary), NCI-H1299 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TNF increase
roscovitine increase
roscovitine TNF no effect upon treatment-induced increase

S177-p - IKKB (human)
Orthologous residues
IKKB (human): S177‑p, IKKB (mouse): S177‑p, IKKB (rat): S177‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  A549 (pulmonary), NCI-H1299 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TNF increase
roscovitine increase
roscovitine TNF no effect upon treatment-induced increase

S181-p - IKKB (human)
Orthologous residues
IKKB (human): S181‑p, IKKB (mouse): S181‑p, IKKB (rat): S181‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  A549 (pulmonary), NCI-H1299 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TNF increase
roscovitine increase
roscovitine TNF no effect upon treatment-induced increase

S276-p - NFkB-p65 (human)
Orthologous residues
NFkB‑p65 (human): S276‑p, NFkB‑p65 (mouse): S276‑p, NFkB‑p65 (rat): S276‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  A549 (pulmonary), NCI-H1299 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TNF no change compared to control
roscovitine increase
TNF roscovitine no effect upon treatment-induced increase
TNF increase
roscovitine TNF inhibit treatment-induced increase

S536-p - NFkB-p65 (human)
Orthologous residues
NFkB‑p65 (human): S536‑p, NFkB‑p65 (mouse): S534‑p, NFkB‑p65 (rat): S535‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  A549 (pulmonary), NCI-H1299 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TNF no change compared to control
roscovitine increase
TNF roscovitine no effect upon treatment-induced increase
TNF increase
roscovitine TNF inhibit treatment-induced increase

S15-p - p53 (human)
Orthologous residues
p53 (human): S15‑p, p53 (mouse): S15‑p, p53 iso2 (mouse): S18‑p, p53 (rat): S15‑p, p53 (rabbit): S15‑p, p53 (monkey): S15‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  A549 (pulmonary), NCI-H1299 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human

S392-p - p53 (human)
Orthologous residues
p53 (human): S392‑p, p53 (mouse): S386‑p, p53 iso2 (mouse): , p53 (rat): S390‑p, p53 (rabbit): S390‑p, p53 (monkey): S392‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  A549 (pulmonary), NCI-H1299 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.